Clinical Trial Update: Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED [Phase 2]

View source ↗

Summary

A Phase 2 trial (PRIMED) evaluating a preventive strategy for IMMU132-related adverse events in triple-negative and HR+/HER2-negative breast cancer has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Sacituzumab Govitecan (Trodelvy) (sacituzumab govitecan)

Snippet

Sponsor: MedSIR | Conditions: Triple Negative Breast Cancer, Breast Cancer | Phase 2 | Status: COMPLETED